Lilly Looks For Japan Rebound After Hit From LOEs

 
• By Lisa Takagi

Although Lilly Japan's 2022 sales declined 13% on the losses of exclusivity for two important products, the subsidiary has high hopes for three new drugs and other indication expansions. Its first-ever decentralized clinical trial involving Japanese patients, for Alzheimer's candidate donanemab, also turned out successfully.

Lilly sees the Japanese market as the largest market for the firm outside the US
Lilly sees the Japanese market as the largest market for the firm outside the US • Source: Shutterstock

More from Japan

More from Focus On Asia